Baxter International Inc. (BAX)

9 members of Congress have disclosed trading BAX — 11 purchases and 10 sales worth an estimated $192,500. Most recent disclosure: Oct 30, 2025.

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Company website ↗

• ROE (-15.01%) — how efficiently the company turns shareholders' money into profit. Negative means it's currently losing money on that equity.
• Profit margin (-9.70%) — of every $1 in sales, this is what's left as profit after all costs.
• Dividend yield (0.91%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.